

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/12, C07K 14/705, 16/28, A61K 38/17, C12Q 1/68, G01N 33/50, A61K 31/70</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/46377</b> <b>(43) International Publication Date:</b> 16 September 1999 (16.09.99)
<b>(21) International Application Number:</b> PCT/EP99/01550 <b>(22) International Filing Date:</b> 10 March 1999 (10.03.99) <b>(30) Priority Data:</b> 98400565.2      11 March 1998 (11.03.98)      EP <b>(71) Applicant (for all designated States except US):</b> SANOFI-SYNTHELABO [FR/FR]; 174, avenue de France, F-75013 Paris (FR). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PARTISETI, Michel [FR/FR]; 72, rue Velpeau, F-92160 Antony (FR). RE-NARD, Stéphane [FR/FR]; 290, avenue Napoléon Bonaparte, F-92500 Rueil Malmaison (FR). <b>(74) Agent:</b> BUREAU D.A. CASALONGA-JOSSE; Morassistrasse 8, D-80469 Munich (DE).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> A HUMAN VANILLOID RECEPTOR-LIKE CATION CHANNEL		
<b>(57) Abstract</b>		
<p>hVRCC polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hVRCC polypeptides and polynucleotides in the design of protocols for the treatment of acute and chronic inflammation, acute and chronic pain, brain diseases, abnormal proliferation and cancer, ulcer, autoimmune diseases, control of viscera innervated by the dorsal root ganglia neurons (for instance control of bladder function or dysfunction), to mimic or antagonize effect of endogenous neurotransmitters and hormones, to inhibit graft rejection by promoting immunosuppression, among others and diagnostic assays for such conditions.</p> <div data-bbox="730 1155 1250 1785"> <p>3.2 Kb →</p> </div>		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## A HUMAN VANILLOID RECEPTOR-LIKE CATION CHANNEL

## FIELD OF INVENTION

5 This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, to the use of such polynucleotides and polypeptides and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to vanilloid  
10 receptor-like channel family, hereinafter referred to as hVRCC (Human Vanilloid Receptor-like Cation Channel). The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides.

## 15 BACKGROUND OF THE INVENTION

Vanilloids are natural compounds which are known to trigger cation permeability in subpopulations of peripheral neurons. These ones, also called "nociceptors", are involved in physiological processes such as transmission to the  
20 central nervous system of noxious stimuli, said stimuli being mechanical, chemical or thermal (Jessel and Kelly, 1991, pp 385-399, Principal of Neural Sciences, third edition, edited by Kandel et al.). Recently, a new cation channel was discovered and isolated from rat (Caterina et  
25 al., 1997, Nature 389 pp 816-824). This channel is activated by vanilloids such as capsaicin and resiniferatoxin and is highly expressed in adult dorsal root ganglia. This channel has also been shown to have significant structural similarities with the "store-operated" calcium channel  
30 family i. e., six putative transmembrane domains . A major functional characteristic of this capsaicin-gated conductance is that it is highly selective for the divalent cation calcium even if it is also permeant to magnesium and monovalent cations such as sodium, potassium and cesium.  
35 This indicates that these channels have an interesting potential as therapeutic targets. Clearly there is a need for identification and characterization of further channels

which can play a role in (i) preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, acute and chronic inflammation, acute and chronic pain, brain diseases, ulcer, abnormal proliferation and cancer, autoimmune diseases, control of viscera innervated by the dorsal root ganglia neurons (for instance control of bladder function or dysfunction) and (ii) mimicking or antagonizing effect of endogenous neurotransmitters and hormones and inhibiting graft rejection by promoting immunosuppression.

#### SUMMARY OF THE INVENTION

In one aspect, the invention relates to hVRCC polypeptides and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such hVRCC polypeptides and polynucleotides. Such uses include the treatment of acute and chronic inflammation, acute and chronic pain, brain diseases, abnormal proliferation and cancer, ulcer, control of viscera innervated by the dorsal root ganglia neurons (for instance control of bladder function or dysfunction), to mimic or antagonize effect of endogenous neurotransmitters and hormones, or to diagnose or treat any disorder related to abnormal expression of these hVRCC polypeptides, among others. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with hVRCC imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate hVRCC activity or levels.

#### TISSUE DISTRIBUTION OF THE hVRCC

The following drawing is illustrative of the embodiments of the invention and is not meant to limit the scope of the invention as encompassed by the claims.

Tissue distribution of the hVRCC was determined by Northern Blot. A 1750bp cDNA probe was obtained from the

hVRCC clone by BstXI digestion and was radiolabelled with [32P]dATP. This probe was used to hybridize 4 membranes representing a population of messenger RNAs from different tissues (indicated on the figure 1,2,3,4) in Express Hyb buffer (Clontech) according to the manufacturer specifications, and washed to a final stringency of 0.1 X SSC 0.1% SDS 55°C. The signal was detected using a Storm (Molecular Dynamics) after a 3 day exposure.

Figure 1 is a Multiple Tissue Northern (Clontech, ref 7760-1) with human heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas mRNA (2mg/lane).

Figure 2 is Human Immune system blot (Clontech, ref 7768-1) with Spleen, lymph nodes, thymus, peripheral blood lymphocytes (PBL), bone marrow, fetal liver mRNA (2mg/lane).

Figure 3 is a Human Brain blot (Clontech, ref 7750-1) with amygdala, caudate nucleus, corpus callosum, hippocampus, total brain, substantia nigra, subthalamic nucleus, and thalamus mRNA (2mg/lane).

Figure 4 is a blot made with monkey DRG total RNA (25 mg), human spinal cord, brain, heart mRNA (2mg/lane), as well as mRNA from human embryonic kidney (HEK293) and Chinese Hamster Ovary (CHO) cell lines (2mg/lane).

hVRCC messenger RNA is transcribed in the brain (especially in the amygdala, substantia nigra and thalamus) and in dorsal root ganglia and spinal cord. hVRCC messenger RNA is also transcribed in the immune system (spleen, lymph nodes, thymus, PBL), lung, placenta and heart.

The localisation of hVRCC pinpoints the role that this new protein can play in some physiological or pathophysiological mechanisms. This tissue distribution allows to propose that hVRCC agonist or antagonists may play a role in acute and chronic inflammation, acute and chronic pain, brain diseases, ulcer, abnormal proliferation and cancer, autoimmune diseases, control of viscera innervated by the DRG neurons (for instance control of bladder function or dysfunction).

Contributors to these tissue distribution results : C. Drouet-Pétre, H. Esnaud, M. Agnel, S. Renard.

## DESCRIPTION OF THE INVENTION

Definitions

The following definitions are provided to facilitate  
5 understanding of certain terms used frequently herein-below.

«hVRCC» refers, among others, to a polypeptide  
comprising the amino acid sequence set forth in SEQ ID NO:2,  
or an allelic variant thereof.

«Receptor Activity» or «Channel Activity» or  
10 «Biological Activity of the Receptor» or «Biological  
Activity of the Channel» refers to the metabolic or  
physiologic function of said hVRCC including similar  
activities or improved activities or these activities with  
decreased undesirable side-effects. Also included are  
15 antigenic and immunogenic activities of said hVRCC.

«hVRCC gene» refers to a polynucleotide comprising the  
nucleotide sequence set forth in SEQ ID NO:1 or allelic  
variants thereof and/or their complements.

«Antibodies» as used herein includes polyclonal and  
20 monoclonal antibodies, chimeric, single chain, and humanized  
antibodies, as well as Fab fragments, including the products  
of a Fab or other immunoglobulin expression library.

«Isolated» means altered «by the hand of man» from the  
natural state. If an «isolated» composition or substance  
25 occurs in nature, it has been changed or removed from its  
original environment, or both. For example, a polynucleotide  
or a polypeptide naturally present in a living animal is not  
«isolated,» but the same polynucleotide or polypeptide  
separated from the coexisting materials of its natural state  
30 is «isolated», as the term is employed herein.

«Polynucleotide» generally refers to any  
polyribonucleotide or polydeoxyribonucleotide, which may be  
unmodified RNA or DNA or modified RNA or DNA.

«Polynucleotides» include, without limitation single- and  
35 double-stranded DNA, DNA that is a mixture of single- and  
double-stranded regions, single- and double-stranded RNA,  
and RNA that is mixture of single- and double-stranded  
regions, hybrid molecules comprising DNA and RNA that may be

single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, «polynucleotide» refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term

5 polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. «Modified» bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to

10 DNA and RNA; thus, «polynucleotide» embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. «Polynucleotide» also embraces relatively short

15 polynucleotides, often referred to as oligonucleotides.

«Polypeptide» refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. «Polypeptide» refers to both short chains,

20 commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. «Polypeptides» include amino acid sequences modified either by natural processes,

25 such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a

30 polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain

35 many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslation natural

processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter et al., «Analysis for protein modifications and nonprotein cofactors», Meth Enzymol (1990) 182:626-646 and Rattan et al., «Protein Synthesis: Posttranslational Modifications and Aging», Ann NY Acad Sci (1992) 663:48-62.

«Variant» as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide.



Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

«Identity» is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. «Identity» per se has an art-recognized meaning and can be calculated using published techniques. See, e.g.: (COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., ed., Oxford University Press, New York, 1988; BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS, Smith, D.W., ed., Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987; and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term «identity» is well known to skilled artisans (Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not

limited to, GCG program package (Devereux, J., et al., Nucleic Acids Research (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S.F. et al., J Molec Biol (1990) 215:403).

As an illustration, by a polynucleotide having a  
5 nucleotide sequence having at least, for example, 95%  
"identity" to a reference nucleotide sequence of SEQ ID NO:  
1 is intended that the nucleotide sequence of the  
polynucleotide is identical to the reference sequence except  
that the polynucleotide sequence may include up to five  
10 point mutations per each 100 nucleotides of the reference  
nucleotide sequence of SEQ ID NO: 1. In other words, to  
obtain a polynucleotide having a nucleotide sequence at  
least 95% identical to a reference nucleotide sequence, up  
to 5% of the nucleotides in the reference sequence may be  
15 deleted or substituted with another nucleotide, or a number  
of nucleotides up to 5% of the total nucleotides in the  
reference sequence may be inserted into the reference  
sequence. These mutations of the reference sequence may  
occur at the 5 or 3 terminal positions of the reference  
20 nucleotide sequence or anywhere between those terminal  
positions, interspersed either individually among  
nucleotides in the reference sequence or in one or more  
contiguous groups within the reference sequence.

Similarly, by a polypeptide having an amino acid  
25 sequence having at least, for example, 95% "identity" to a  
reference amino acid sequence of SEQ ID NO:2 is intended  
that the amino acid sequence of the polypeptide is identical  
to the reference sequence except that the polypeptide  
sequence may include up to five amino acid alterations per  
30 each 100 amino acids of the reference amino acid of SEQ ID  
NO: 2. In other words, to obtain a polypeptide having an  
amino acid sequence at least 95% identical to a reference  
amino acid sequence, up to 5% of the amino acid residues in  
the reference sequence may be deleted or substituted with  
35 another amino acid, or a number of amino acids up to 5% of  
the total amino acid residues in the reference sequence may  
be inserted into the reference sequence. These alterations  
of the reference sequence may occur at the amino or carboxy

terminal positions of the reference amino acid sequence or  
anywhere between those terminal positions, interspersed  
either individually among residues in the reference sequence  
or in one or more contiguous groups within the reference  
5 sequence.

### Polypeptides of the Invention

In one aspect, the present invention relates to hVRCC  
polypeptides. The hVRCC polypeptides include the polypeptide  
10 of SEQ ID NO:2, as well as polypeptides comprising the amino  
acid sequence of SEQ ID NO:2, and polypeptides comprising  
the amino acid sequence which have at least 80% identity to  
that of SEQ ID NO:2 over its entire length, and still more  
preferably at least 90% identity, and even still more  
15 preferably at least 95% identity to SEQ ID NO: 2.  
Furthermore, those with at least 97-99% are highly  
preferred. Also included within hVRCC polypeptides are  
polypeptides having the amino acid sequence which have at  
least 80% identity to the polypeptide having the amino acid  
20 sequence of SEQ ID NO: 2 over its entire length, and still  
more preferably at least 90% identity, and even still more  
preferably at least 95% identity to SEQ ID NO: 2.  
Furthermore, those with at least 97-99% are highly  
preferred. Preferably hVRCC polypeptides exhibit at least  
25 one biological activity of the receptor.

The hVRCC polypeptides may be in the form of the  
«mature» protein or may be a part of a larger protein such  
as a fusion protein. It is often advantageous to include an  
additional amino acid sequence which contains secretory or  
30 leader sequences, pro-sequences, sequences which aid in  
purification such as multiple histidine residues, or an  
additional sequence for stability during recombinant  
production.

Fragments of the hVRCC polypeptides are also included  
35 in the invention. A fragment is a polypeptide having an  
amino acid sequence that entirely is the same as part, but  
not all, of the amino acid sequence of the aforementioned  
hVRCC polypeptides. As with hVRCC polypeptides, fragments

may be «free-standing,» or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, 5 for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, and 101 to the end of hVRCC polypeptide. In this context «about» includes the particularly recited ranges larger or smaller by several, 5, 4, 3, 2 or 1 amino acid at either extreme or at both 10 extremes.

Preferred fragments include, for example, truncation polypeptides having the amino acid sequence of hVRCC polypeptides, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous 15 series of residues that includes the carboxyl terminus or deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl terminus. Also preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha- 20 helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, 25 substrate binding region, and high antigenic index regions. Other preferred fragments are biologically active fragments. Biologically active fragments are those that mediate receptor or channel activity, including those with a similar activity or an improved activity, or with a decreased 30 undesirable activity. Also included are those that are antigenic or immunogenic in an animal, especially in a human.

Preferably, all of these polypeptide fragments retain the biological activity of the receptor, including antigenic 35 activity. Variants of the defined sequence and fragments also form part of the present invention. Preferred variants are those that vary from the referents by conservative amino acid substitutions i.e., those that substitute a residue

with another of like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination.

The hVRCC polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

15

#### Polynucleotides of the Invention

Another aspect of the invention relates to hVRCC polynucleotides. hVRCC polynucleotides include isolated polynucleotides which encode the hVRCC polypeptides and fragments, and polynucleotides closely related thereto. More specifically, hVRCC polynucleotides of the invention include a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO:1 encoding a hVRCC polypeptide of SEQ ID NO: 2, and polynucleotide having the particular sequence of SEQ ID NO:1. hVRCC polynucleotides further include a polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the hVRCC polypeptide of SEQ ID NO:2 over its entire length, and a polynucleotide that is at least 80% identical to that having SEQ ID NO:1 over its entire length. In this regard, polynucleotides at least 90% identical are particularly preferred, and those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred and those with at least 98-99% are most highly preferred, with at least 99% being the most preferred. Also included under hVRCC polynucleotides are a nucleotide sequence which has sufficient identity to a nucleotide sequence contained in SEQ ID NO:1 or contained in the cDNA

35

insert in the plasmid deposited with the ATCC Deposit number 209625 to hybridize under conditions useable for amplification or for use as a probe or marker. Moreover, hVRCC polynucleotide includes nucleotide sequences having at least 80% identity to a nucleotide sequence encoding the hVRCC polypeptide expressed by the cDNA insert deposited at the ATCC with Deposit Number 209625, and a nucleotide sequence comprising at least 15 contiguous nucleotides of such cDNA insert. In this regard, polynucleotides at least 90% identical are particularly preferred, and those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred and those with at least 98-99% are most highly preferred, with at least 99% being the most preferred. The invention also provides polynucleotides which are complementary to all the above hVRCC polynucleotides.

A deposit containing a human hVRCC cDNA has been deposited with the American Type Culture Collection (ATCC), 12301 Park Lawn Drive, Rockville, Maryland 20852, USA, on February 10, 1998, and assigned ATCC Deposit Number 209625. The deposited material (clone) is a DH5-a strain containing the expression vector bluescript (pBS-SK, Stratagene) that further contains the hVRCC cDNA, referred to as «hVRCC" upon deposit. The cDNA insert is within EcoRI-XhoI site(s) in the vector. The nucleotide sequence of the polynucleotides contained in the deposited material, as well as the amino acid sequence of the polypeptide encoded thereby, are controlling in the event of any conflict with any description of sequences herein.

The deposit has been made under the terms of the Budapest Treaty on the international recognition of the deposit of micro-organisms for purposes of patent procedure. The strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent.

hVRCC of the invention is structurally related to other proteins of the store-operated calcium channel family, as shown by the results of sequencing the cDNA of Table 1 (SEQ

ID NO:1) encoding human hVRCC. The cDNA sequence of SEQ ID NO:1 contains an open reading frame (nucleotide number 402 to 2696) encoding a polypeptide of 763 amino acids of SEQ ID NO:2. Amino acid sequence of Table 2 (SEQ ID NO:2) has about 5 49.6%) identity (using blastP version 1.4, GCG program package) in 681 amino acid residues with the rat vanilloid receptor subtype 1 (VR1) protein (accession number: AF029310, Caterina et al., 1997, Nature 389, pp816-824). Nucleotide sequence of Table 1 (SEQ ID NO:1) has about 61% 10 identity (using blastN version 1.4, GCG program package) in 2069 (166 to 2235) nucleotide residues with the VR1 cDNA (accession number: AF029310).

Table 1a

GGCTAGCCTGTCCTGACAGGGGAGAGTTAAGCTCCCGTTCTCCACCGTGCCGGCTGGCCAGGTGGGCTGAGGGTGACCGAGAGACC  
AGAACCTGCTTGTCTGGAGCTTAGTGCTCAGAGCTGGGGAGGGAGGTTCCGCCGCTCCTCTGCTGTCAGCGCCGGCAGCCCCCTCCC  
GCTTCACTTCTCCCGCAGCCCCCTGCTACTGAGAAGCTCCGGGATCCAGCAGCCGCCACGCCCTGGCCTCAGCCTGCGGGGCTCC  
AGTCAGGCCAACACCGACGCGCAGCTGGGAGGAAGACAGGACCCTTGACATCTCCATCTGCACAGAGGTCTGGCTGGACCGAGCA  
GCCTCCTCCTCTAGGATGACCTCACCTCCAGCTCTCCAGTTTTTCAGGTTGGAGACATTAGATGGAGGCCAAGAAGATGGCTCTG  
AGGCGGACAGAGGAAAGCTGGATTTTGGGAGCGGGCTGCCTCCCATGGAGTCACAGTTCCAGGGCGAGGACCGGAAATTCGCCCT  
CAGATAAGAGTCAACCTCAACTACCGAAAGGGAACAGGTGCCAGTCAGCCGGATCCAAACCGATTTGACCGAGATCGGCTCTTCAA  
TGCGGTCTCCCGGGGTGTCCCGAGGATCTGGCTGGACTTCAGAGTACCTGAGCAAGACCAGCAAGTACCTCACCGACTCGGAAT  
ACACAGAGGGCTCCACAGGTAAGACGTGCCTGATGAAGGCTGTGCTGAACCTTAAGGACGGAGTCAATGCCTGCATTCTGCCACTG  
CTGCAGATCGACAGGACTCTGGCAATCTCAGCCCCCTGGTAAATGCCAGTGACAGATGACTATTACCGAGGCCACAGCGCTCT  
GCACATCGCCATTGAGAAGAGGAGTCTGCAGTGTGTGAAGCTCCTGGTGGAGAATGGGGCCAATGTGCATGCCCGGGCTGCGGCC  
GCTTCTCCAGAAGGGCCAAGGGACTTGCTTTTATTTTCGGTGAGCTACCCCTCTCTTTGGCCGCTTGACCAAGCAGTGGGATGTG  
GTAAGCTACCTCCTGGAGAACCACACCAGCCCGCCAGCCTGCAGGCCACTGACTCCAGGGCAACACAGTCTGCATGCCCTAGT  
GATGATCTCGGACAACTCAGCTGAGAACATTGCACTGGTGACCAGCATGTATGATGGGCTCCTCCAAGCTGGGGCCCGCTCTGCC  
CTACCGTGCAGCTTGAGGACATCCGCAACCTGCAGGATCTCACGCCCTCTGAAGCTGGCCGCAAGGAGGGCAAGATCGAGATTTTC  
AGGCACATCCTGCAGCGGGAGTTTTTCAGGACTGAGCCACCTTTCCCGAAAGTTCACCGAGTGGTGCTATGGGCCTGTCCGGGTGTC  
GCTGTATGACCTGGCTTCTGTGGACAGCTGTGAGGAGAACTCAGTGCTGGAGATCATTCCTTTTATTGCAAGAGCCCCGACCCGAC  
ACCGAATGGTCGTTTTTGGAGCCCCGAAACAACTGCTGCAGGCGAAATGGGATCTGCTCATCCCCAAGTTCTTCTTAAACTTCCTG  
TGTAATCTGATCTACATGTTTATCTTACCGCTGTTGCTTACCATCAGCCTACCTGAAGAAGGCCGCCCTCACCTGAAAGCGGA  
GGTTGGAAACTCCATGCTGCTGACGGGCCACATCCTTATCCTGCTAGGGGGGATCTACCTCCTCGTGGGCCAGCTGTGGTACTTCT  
GGCGGCGCCACGTGTTTATCTGGATCTCGTTTATAGACAGCTACTTTGAAATCCTCTTCTGTTCCAGGCCCTGCTCACAGTGGTG  
TCCCAGGTGCTGTGTTTCTGGCCATCGAGTGGTACCTGCCCTGCTGTGTCTGCGCTGGTGCTGGGCTGGCTGAACCTGCTTTA  
CTATACAGTGGCTTCCAGCACACAGGCATCTACAGTGTGATGATCCAGAAGGTATCCTGCGGGACCTGCTGCGCTTCTTCTGA  
TCTACTTAGTCTTCTTTTCGGCTTCGCTGTAGCCCTGGTGAGCCTGAGCCAGGAGGCTTGGCGCCCCGAAGCTCTACAGGCCCC  
AATGCCACAGAGTCAGTGCAGCCCATGGAGGGACAGGAGGACGAGGGCAACGGGGCCAGTACAGGGGTATCCTGGAAGCCTCCTT  
GGAGCTCTTCAAATTCACCATCGGCATGGGCGAGCTGGCCTTCCAGGAGCAGTGCAGTTCCGCGGCATGGTGCTGCTGCTGCTGC  
TGGCCTACGTGCTGCTCACCTACATCCTGCTGCTCAACATGCTCATCGCCCTCATGAGCGAGACCGTCAACAGTGTGCCACTGAC  
AGCTGGAGCATCTGGAAGCTGCAGAAAGCCATCTCTGTCTGGAGATGGAGAATGGCTATTGGTGGTGAGGAAGAAGCAGCGGGC  
AGGTGTGATGCTGACCGTTGGCACTAAGCCAGATGGCAGCCCCGATGAGCGCTGGTGTCTCAGGGTGGAGGAGGTGAAGTGGGCTT  
CATGGGAGCAGACGCTGCCTACGCTGTGTGAGGACCCGTGAGGGGAGGTGTCCCTCGAACTCTCGAGAACCCTGTCTGGCTTCC  
CCTCCCAAGGAGGATGAGGATGGTGCCTCTGAGGAAACTATGTGCCGTCCAGCTCCTCCAGTCCAACTGATGGCCAGATGCAG  
CAGGAGGCCAGAGGACAGAGCAGAGGATCTTCCAACCATCTGCTGGCTCTGGGGTCCCAGTGAATTCTGGTGGCAAATATATA  
TTTTCACTAACTAAAAAAAAAAAAAAAAAAAA

<sup>a</sup> A nucleotide sequence of a human hVRCC. SEQ ID NO: 1.



Allelic variants of this sequence have been identified such as a t in position 374, a g in position 750, a c in position 787, and an agg insertion after position 1612, resulting in a glutamine amino-acid insertion in the corresponding position of the protein.

Table 2b

```

MTSPSSSPVFRLETLDGGQEDGSEADRGKLDGSGLPPEMQFQGEDRKFAPIRVNLNRYKGTGASQPDNRFDRDLFNAVSRG
VPEDLAGLPEYLSKTSKYLTDSYETEGSTGKTCMLKAVLNKLDGVNACILPLLQIDRDSGNPQPLVNAQCTDDYYRGHSALHIAIE
KRSLLQCVKLLVENGANVHARACGRFFQKGQGTCTFYFGEPLSLAACTKQWDVVSYLLENPHQPASLQATDSQGNITVLHALVMISDN
SAENIALVTSMYDGLLQAGARLCPTVQLEDIRNLQDLTPLKLAKEGKIEIFRHILQREFSGLSHLRSKFTWCYGPVRVSLYDLA
SVDSCEENSVLIEIIAFHCKSPHRHRMVLEPLNKLQAKWDLIPKFFLNFLCNLIYMFIFTAVAYHQPTLKKAAAPHLKAEVGNM
LLTGHIILILGGIYLLVGQLWYFWRHVFIIWISFIDSYFEILFLFQALLTVVSQVLCFLAIEWYLPLLVSALVLGWLNLLEYTRGF
QHTGIYSVMIQKVILRDLLRFLLIYLVFLFGFAVALVSLSQEAWRPEAPTGNATESVQPMEGQEDEGNGAQYRGILEASLELFKF
TIGMGELAFQEQLHFRGMVLLLLLAYVLLTYILLNMLIALMSETVNSVATDSWSIWKLQKAISVLEMENGYWWCRKKQRAGVMLT
VGTKPDGSPDERWCFRVEEVNWSWEQTLPTCEDPSGAGVPRTLENPVLASPPKEDEGASEENYVPVQLQSN

```

<sup>b</sup> An amino acid sequence of a human hVRCC. SEQ ID NO: 2.

One polynucleotide of the present invention encoding hVRCC may be obtained using standard cloning and screening, from a cDNA library derived from mRNA in macrophages using the expressed sequence tag (EST) analysis (Adams, M.D., et al. Science (1991) 252:1651-1656; Adams, M.D. et al., Nature, (1992) 355:632-634; Adams, M.D., et al., Nature (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

The nucleotide sequence encoding hVRCC polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in Table 1 (nucleotide number 361 to 2649 of SEQ ID NO:1), or it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2.

When the polynucleotides of the invention are used for the recombinant production of hVRCC polypeptide, the polynucleotide may include the coding sequence for the mature polypeptide or a fragment thereof, by itself; the

coding sequence for the mature polypeptide or fragment in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions.

5 For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described  
10 in Gentz et al., Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

15 Further preferred embodiments are polynucleotides encoding hVRCC variants comprising the amino acid sequence of hVRCC polypeptide of Table 2 (SEQ ID NO:2) in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acid residues are substituted, deleted or added, in any combination.

20 The present invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the present invention especially relates to polynucleotides which hybridize under stringent conditions to the herein above-described polynucleotides. As  
25 herein used, the term «stringent conditions» means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.

Polynucleotides of the invention, which are identical or sufficiently identical to a nucleotide sequence contained  
30 in SEQ ID NO:1 or a fragment thereof, or to the cDNA insert in the plasmid deposited at the ATCC with Deposit Number 209625 or a fragment thereof, may be used as hybridization probes for cDNA and genomic DNA, to isolate full-length cDNAs and genomic clones encoding hVRCC and to isolate cDNA  
35 and genomic clones of other genes that have a high sequence similarity to the hVRCC gene. Such hybridization techniques are known to those of skill in the art. Typically these nucleotide sequences are 80% identical, preferably 90%

identical, more preferably 95% identical to that of the referent. The probes generally will comprise at least 15 nucleotides. Preferably, such probes will have at least 30 nucleotides and may have at least 50 nucleotides.

- 5 Particularly preferred probes will range between 30 and 50 nucleotides.

In one embodiment, to obtain a polynucleotide encoding hVRCC polypeptide comprises the steps of screening an appropriate library under stringent hybridization conditions  
10 with a labeled probe having the SEQ ID NO: 1 or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to those of skill in the art. Stringent hybridization conditions are as defined above or  
15 alternatively conditions under overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20  
20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

The polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments and diagnostics to animal and human disease.

25

### **Vectors, Host Cells, Expression**

The present invention also relates to vectors which comprise a polynucleotide or polynucleotides of the present invention, and host cells which are genetically engineered  
30 with vectors of the invention and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

- 35 For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells

can be effected by methods described in many standard laboratory manuals, such as Davis et al., BASIC METHODS IN MOLECULAR BIOLOGY (1986) and Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used. Such systems include, among others, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL (supra).

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or

into the extracellular environment, appropriate secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

- 5        If the hVRCC polypeptide is to be expressed for use in screening assays, generally, it is preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If hVRCC polypeptide is secreted into the  
10 medium, the medium can be recovered in order to recover and purify the polypeptide; if produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

- hVRCC polypeptides can be recovered and purified from  
15 recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and  
20 lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.
- 25

### Diagnostic Assays

This invention also relates to the use of hVRCC polynucleotides for use as diagnostic reagents. Detection of a mutated form of hVRCC gene associated with a dysfunction will provide a diagnostic tool that can add to or define a diagnosis of a disease or susceptibility to a disease which results from under-expression, over-expression or altered expression of hVRCC. Individuals carrying mutations in the hVRCC gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled hVRCC nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al., Science (1985) 230:1242. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method. See Cotton et al., Proc Natl Acad Sci USA (1985) 85: 4397-4401. In another embodiment, an array of oligonucleotides probes comprising hVRCC nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability. (See for example: M.Chee et al., Science, Vol 274, pp 610-613

(1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to inflammation and pain (both acute and chronic), brain diseases, abnormal proliferation and cancer, autoimmune diseases, , control of viscera innervated by the dorsal root ganglia neurons (for instance control of bladder function or dysfunction) through detection of mutation in the hVRCC gene by the methods described.

10 In addition, inflammation and pain (both acute and chronic), brain diseases, abnormal proliferation and cancer, can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of hVRCC polypeptide or hVRCC mRNA.

15 Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to

20 determine levels of a protein, such as a hVRCC, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

### Chromosome Assays

The nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

25

### Antibodies

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them can also be used as immunogens to produce antibodies immunospecific for the hVRCC polypeptides. The term «immunospecific» means that the antibodies have substantial greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against the hVRCC polypeptides can be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique which provides



antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole et al., MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

Antibodies against hVRCC polypeptides may also be employed to treat cerebral and cardiac and renal ischemias, brain and cardiac diseases, inflammation, pain, control of viscera innervated by the dorsal root ganglia neurons (for instance control of bladder function or dysfunction), to mimic or antagonize effect of endogenous neurotransmitters and hormones, or to diagnose or treat any disorder related to abnormal expression of said hVRCC polypeptides, among others.

#### Vaccines/immunological products

Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with hVRCC polypeptide, or a fragment thereof, adequate to produce antibody and/or T cell immune response to protect said animal from inflammation and pain (both acute and chronic), brain diseases, ulcer, abnormal proliferation and cancer, autoimmune diseases, to mimic or antagonize effect of endogenous neurotransmitters and hormones, or to diagnose or treat any disorder related to abnormal expression of the hVRCC polypeptide, among others. Yet another aspect of the

invention relates to a method of inducing immunological response in a mammal which comprises, delivering hVRCC polypeptide via a vector directing expression of hVRCC polynucleotide in vivo in order to induce such an  
5 immunological response to produce antibody to protect said animal from diseases.

Further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological  
10 response in that mammal to a hVRCC polypeptide wherein the composition comprises a hVRCC polypeptide or hVRCC gene. The vaccine formulation may further comprise a suitable carrier. Since hVRCC polypeptide may be broken down in the stomach, it is preferably administered parenterally (including  
15 subcutaneous, intramuscular, intravenous, intradermal etc. injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the  
20 formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may  
25 be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the  
30 art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

### Screening Assays

35 The hVRCC polypeptide of the present invention may be employed in a screening process for compounds which bind the channel and which activate (agonists) or inhibit activation of (antagonists) the channel polypeptide of the present

invention. Thus, polypeptides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These  
5 substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).

hVRCC polypeptides are implicated in many biological functions, and possibly pathologies. Accordingly, it is  
10 desirous to find compounds and drugs which stimulate hVRCC on the one hand and which can inhibit the function of hVRCC on the other hand. In general, agonists are employed for therapeutic and prophylactic purposes for such conditions as to mimic effect of endogenous neurotransmitters and  
15 hormones. Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions as inflammation and pain (both acute and chronic), brain diseases, ulcer, abnormal proliferation and cancer, autoimmune diseases, control of viscera innervated by the  
20 dorsal root ganglia neurons (for instance control of bladder function or dysfunction), to antagonize effect of endogenous neurotransmitters and hormones and to inhibit graft rejection by promoting immunosuppression.

In general, such screening procedures involve producing  
25 appropriate cells which express the receptor polypeptide of the present invention on the surface thereof. Such cells include cells from mammals, yeast, Drosophila or E. coli. Cells expressing the receptor (or cell membrane containing the expressed receptor) are then contacted with a test  
30 compound to observe binding, or stimulation or inhibition of a functional response.

The assays may simply test binding of a candidate compound wherein adherence to the cells bearing the channel is detected by means of a label directly or indirectly  
35 associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the channel, using

detection systems appropriate to the cells bearing the channel at their surfaces. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Standard methods for conducting such screening assays are well understood in the art.

The recording of hVRCC channel activity may be carried out either by membrane voltage analysis of transfected cells or microinjected xenope oocytes, directly (patch-clamp for example) or indirectly (fluorescent probes sensitive to changes of intracellular free calcium concentration such as fura-2 and calcium green, Molecular Probes). The assays may simply test binding of a candidate compound wherein adherence to the cells bearing the channel is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the channel, using detection systems appropriate to the cells bearing the channel at their surfaces. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Standard methods for conducting such screening assays are well understood in the art.

Examples of potential hVRCC antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligand of the hVRCC, e.g., a fragment of the ligand, or small molecules which bind to the receptor but do not elicit a response, so that the activity of the channel is prevented.

#### **Prophylactic and Therapeutic Methods**

This invention provides methods of treating abnormal conditions related to both an excess of and insufficient amounts of hVRCC activity.

If the activity of hVRCC is in excess, several

approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit activation by blocking binding of ligands to the hVRCC, or by inhibiting a second signal, and thereby alleviating the abnormal condition.

In another approach, soluble forms of hVRCC polypeptides still capable of binding the ligand in competition with endogenous hVRCC may be administered. Typical embodiments of such competitors comprise fragments of the hVRCC polypeptide.

In still another approach, expression of the gene encoding endogenous hVRCC can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered. See, for example, O'Connor, J Neurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Alternatively, oligonucleotides which form triple helices with the gene can be supplied. See, for example, Lee et al., Nucleic Acids Res (1979) 6:3073; Cooney et al., Science (1988) 241:456; Dervan et al., Science (1991) 251:1360. These oligomers can be administered per se or the relevant oligomers can be expressed in vivo.

For treating abnormal conditions related to an under-expression of hVRCC and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates hVRCC, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of hVRCC by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced

into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest.

5 These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo. For overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human  
10 Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996).

#### Formulation and Administration

Peptides, such as the soluble form of hVRCC  
15 polypeptides, and agonists and antagonist peptides or small molecules, may be formulated in combination with a suitable pharmaceutical carrier. Such formulations comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or  
20 excipient. Such carriers include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. Formulation should suit the mode of administration, and is well within the skill of the art. The invention further relates to pharmaceutical packs and  
25 kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other  
30 compounds, such as therapeutic compounds.

Preferred forms of systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be  
35 used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if properly formulated in enteric or encapsulated

formulations, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like.

5 The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100  $\mu\text{g/kg}$  of subject. Wide variations in the needed dosage, however, are to be expected  
10 in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted  
15 using standard empirical routines for optimization, as is well understood in the art.

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as «gene therapy» as described above. Thus, for  
20 example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide ex vivo, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

25

### Examples

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in  
30 detail. The examples illustrate, but do not limit the invention.

#### Example 1

##### Cloning the Human hVRCC cation Channel

35

The sequence of the hVRCC cation channel was first identified by searching a database containing approximately 2 million human ESTs, which was generated using high

throughput automated DNA sequence analysis of randomly selected human cDNA clones (Adams, M.D. et al., Nature 377:3-174 (1995); Adams, M.D. et al., Nature 355:632-634 (1992); and Adams, M.D. et al., Science 252:1651-1656 (1991)). Sequence homology comparisons of each EST were performed against the GenBank database using the blastn and tblastn algorithms (Altschul, S.F. et al., J. Mol. Biol. 215:403-410 (1990)). A specific homology search using the known rat VR1 amino acid sequence against this human EST database revealed one EST, from a macrophage cDNA library, with approximatively 60% similarity to VR1. The sequence comparison suggested that it contained the complete open reading frame of a new protein. Sequence of the gene was confirmed by double strand DNA sequencing using the TaqFs (Perkin Elmer) and the gene was shown to be completely new by a blast search against Genbank release 103. The entire hVRCC coding region containing the EcoRI-XhoI fragments was inserted into the expression vector bluescript (Stratagene).

## 20 Example 2

### Cloning and Expression of hVRCC in Mammalian Cells

A typical mammalian expression vector contains the promoter element, which mediates the initiation of transcription of mRNA, the protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription can be achieved with the early and late promoters from SV40, the long terminal repeats (LTRS) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter). Suitable expression vectors for use in practicing the present invention include, for example, vectors such as PSVL and PMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146) and pBC12MI (ATCC 67109) and pcDNA3



(Invitrogen). Mammalian host cells that could be used include, human HEK 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and mouse L cells and Chinese hamster ovary (CHO) cells.

5        Alternatively, the gene can be expressed in stable cell lines that contain the gene integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, zeocin or hygromycin allows the identification and isolation of the transfected cells.

10        The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful to develop cell lines that carry several hundred or even several thousand copies of the gene of interest. Another useful selection  
15        marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem. J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992)). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines  
20        contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

      The expression vector pCMVsport3.0 contains the strong promoter (CMV) of the Cytomegalovirus. Multiple cloning  
25        sites, e.g., with the restriction enzyme cleavage sites EcoRI, XhoI, facilitate the cloning of the gene of interest.

### Example 3

#### Tissue distribution of hVRCC mRNA expression

30

      Northern blot analysis can be carried out to examine hVRCC gene expression in human tissues, using methods described by, among others, Sambrook et al., cited above. A cDNA probe containing the entire nucleotide sequence of the  
35        hVRCC protein can be labeled with <sup>32</sup>P using the Rediprime™ DNA labeling system (Amersham Life Science, Arlington, IL), according to manufacturer's instructions. After labeling, the probe can be purified using a CHROMA SPIN- 100 column

(Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe was then used to examine various human tissues for hVRCC mRNA.

Multiple Tissue Northern (MTN) blots containing various human tissues can be obtained from Clontech and examined with the labeled probe using ExpressHyb<sup>®</sup> hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots can be mounted and exposed to film at -70°C overnight, and films developed according to standard procedures. See figures 1,2,3,4.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples.

Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of all publications (including patents, patent applications, journal articles, laboratory manuals, books, or other documents) cited herein are incorporated by reference.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

## (i) APPLICANT:

(A) NAME: SYNTHELABO  
(B) STREET: 22 avenue Galilee  
(C) CITY: LE PLESSIS-ROBINSON  
10 (E) COUNTRY: FRANCE  
(F) POSTAL CODE (ZIP): 92350  
(G) TELEPHONE: (33) 1 45 37 56 76

(ii) TITLE OF INVENTION: Human vanilloid receptor-like cation  
15 channel

(iii) NUMBER OF SEQUENCES: 2

## (iv) COMPUTER READABLE FORM:

20 (A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

25

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 2783 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: circular

35 (ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

40 (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

## (ix) FEATURE:

45 (A) NAME/KEY: 5'UTR  
(B) LOCATION:1..360

## (ix) FEATURE:

(A) NAME/KEY: CDS  
50 (B) LOCATION:361..2649

## (ix) FEATURE:

(A) NAME/KEY: 3'UTR  
(B) LOCATION:2650..2783

55 (ix) FEATURE:

(A) NAME/KEY: allele  
(B) LOCATION:replace(374, "t")

## (ix) FEATURE:

60 (A) NAME/KEY: allele

(B) LOCATION:replace(750, "g")

(ix) FEATURE:

(A) NAME/KEY: allele

5 (B) LOCATION:replace(787, "c")

(ix) FEATURE:

(A) NAME/KEY: allele

(B) LOCATION:replace(1612, "cagg")

10 (D) OTHER INFORMATION:/label= GLUTAMINE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

15 GGCTAGCCTG TCCTGACAGG GGAGAGTTAA GCTCCCGTTC TCCACCGTGC CGGCTGGCCA  
60

GGTGGGCTGA GGGTGACCGA GAGACCAGAA CCTGCTTGCT GGAGCTTAGT GCTCAGAGCT  
120

20 GGGGAGGGAG GTTCCGCCGC TCCTCTGCTG TCAGCGCCGG CAGCCCCTCC CGGCTTCACT  
180

TCCTCCCGCA GCCCCTGCTA CTGAGAAGCT CCGGGATCCC AGCAGCCGCC ACGCCCCTGGC  
25 240

CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC ACCGACGCGC AGCTGGGAGG AAGACAGGAC  
300

30 CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG  
360

ATG ACC TCA CCC TCC AGC TCT CCA GTT TTC AGG TTG GAG ACA TTA GAT  
408

35 Met Thr Ser Pro Ser Ser Ser Pro Val Phe Arg Leu Glu Thr Leu Asp  
1 5 10 15

GGA GGC CAA GAA GAT GGC TCT GAG GCG GAC AGA GGA AAG CTG GAT TTT  
456

40 Gly Gly Gln Glu Asp Gly Ser Glu Ala Asp Arg Gly Lys Leu Asp Phe  
20 25 30

GGG AGC GGG CTG CCT CCC ATG GAG TCA CAG TTC CAG GGC GAG GAC CGG  
504

45 Gly Ser Gly Leu Pro Pro Met Glu Ser Gln Phe Gln Gly Glu Asp Arg  
35 40 45

AAA TTC GCC CCT CAG ATA AGA GTC AAC CTC AAC TAC CGA AAG GGA ACA  
552

50 Lys Phe Ala Pro Gln Ile Arg Val Asn Leu Asn Tyr Arg Lys Gly Thr  
50 55 60

GGT GCC AGT CAG CCG GAT CCA AAC CGA TTT GAC CGA GAT CGG CTC TTC  
600

55 Gly Ala Ser Gln Pro Asp Pro Asn Arg Phe Asp Arg Asp Arg Leu Phe  
65 70 75 80

AAT GCG GTC TCC CGG GGT GTC CCC GAG GAT CTG GCT GGA CTT CCA GAG  
648

60

INSDOCID: <WO\_\_9946377A2\_I\_>

Leu Leu Gln Ala Gly Ala Arg Leu Cys Pro Thr Val Gln Leu Glu Asp  
 275 280 285

5 ATC CGC AAC CTG CAG GAT CTC ACG CCT CTG AAG CTG GCC GCC AAG GAG  
 1272  
 Ile Arg Asn Leu Gln Asp Leu Thr Pro Leu Lys Leu Ala Ala Lys Glu  
 290 295 300

10 GGC AAG ATC GAG ATT TTC AGG CAC ATC CTG CAG CGG GAG TTT TCA GGA  
 1320  
 Gly Lys Ile Glu Ile Phe Arg His Ile Leu Gln Arg Glu Phe Ser Gly  
 305 310 315 320

15 CTG AGC CAC CTT TCC CGA AAG TTC ACC GAG TGG TGC TAT GGG CCT GTC  
 1368  
 Leu Ser His Leu Ser Arg Lys Phe Thr Glu Trp Cys Tyr Gly Pro Val  
 325 330 335

20 CGG GTG TCG CTG TAT GAC CTG GCT TCT GTG GAC AGC TGT GAG GAG AAC  
 1416  
 Arg Val Ser Leu Tyr Asp Leu Ala Ser Val Asp Ser Cys Glu Glu Asn  
 340 345 350

25 TCA GTG CTG GAG ATC ATT GCC TTT CAT TGC AAG AGC CCG CAC CGA CAC  
 1464  
 Ser Val Leu Glu Ile Ile Ala Phe His Cys Lys Ser Pro His Arg His  
 355 360 365

30 CGA ATG GTC GTT TTG GAG CCC CTG AAC AAA CTG CTG CAG GCG AAA TGG  
 1512  
 Arg Met Val Val Leu Glu Pro Leu Asn Lys Leu Leu Gln Ala Lys Trp  
 370 375 380

35 GAT CTG CTC ATC CCC AAG TTC TTC TTA AAC TTC CTG TGT AAT CTG ATC  
 1560  
 Asp Leu Leu Ile Pro Lys Phe Phe Leu Asn Phe Leu Cys Asn Leu Ile  
 385 390 395 400

40 TAC ATG TTC ATC TTC ACC GCT GTT GCC TAC CAT CAG CCT ACC CTG AAG  
 1608  
 Tyr Met Phe Ile Phe Thr Ala Val Ala Tyr His Gln Pro Thr Leu Lys  
 405 410 415

45 AAG GCC GCC CCT CAC CTG AAA GCG GAG GTT GGA AAC TCC ATG CTG CTG  
 1656  
 Lys Ala Ala Pro His Leu Lys Ala Glu Val Gly Asn Ser Met Leu Leu  
 420 425 430

50 ACG GGC CAC ATC CTT ATC CTG CTA GGG GGG ATC TAC CTC CTC GTG GGC  
 1704  
 Thr Gly His Ile Leu Ile Leu Leu Gly Gly Ile Tyr Leu Leu Val Gly  
 435 440 445

55 CAG CTG TGG TAC TTC TGG CGG CGC CAC GTG TTC ATC TGG ATC TCG TTC  
 1752  
 Gln Leu Trp Tyr Phe Trp Arg Arg His Val Phe Ile Trp Ile Ser Phe  
 450 455 460

60 ATA GAC AGC TAC TTT GAA ATC CTC TTC CTG TTC CAG GCC CTG CTC ACA  
 1800

Ile Asp Ser Tyr Phe Glu Ile Leu Phe Leu Phe Gln Ala Leu Leu Thr  
 465 470 475 480  
 5 GTG GTG TCC CAG GTG CTG TGT TTC CTG GCC ATC GAG TGG TAC CTG CCC  
 1848  
 Val Val Ser Gln Val Leu Cys Phe Leu Ala Ile Glu Trp Tyr Leu Pro  
 485 490 495  
 10 CTG CTT GTG TCT GCG CTG GTG CTG GGC TGG CTG AAC CTG CTT TAC TAT  
 1896  
 Leu Leu Val Ser Ala Leu Val Leu Gly Trp Leu Asn Leu Leu Tyr Tyr  
 500 505 510  
 15 ACA CGT GGC TTC CAG CAC ACA GGC ATC TAC AGT GTC ATG ATC CAG AAG  
 1944  
 Thr Arg Gly Phe Gln His Thr Gly Ile Tyr Ser Val Met Ile Gln Lys  
 515 520 525  
 20 GTC ATC CTG CGG GAC CTG CTG CGC TTC CTT CTG ATC TAC TTA GTC TTC  
 1992  
 Val Ile Leu Arg Asp Leu Leu Arg Phe Leu Leu Ile Tyr Leu Val Phe  
 530 535 540  
 25 CTT TTC GGC TTC GCT GTA GCC CTG GTG AGC CTG AGC CAG GAG GCT TGG  
 2040  
 Leu Phe Gly Phe Ala Val Ala Leu Val Ser Leu Ser Gln Glu Ala Trp  
 545 550 555 560  
 30 CGC CCC GAA GCT CCT ACA GGC CCC AAT GCC ACA GAG TCA GTG CAG CCC  
 2088  
 Arg Pro Glu Ala Pro Thr Gly Pro Asn Ala Thr Glu Ser Val Gln Pro  
 565 570 575  
 35 ATG GAG GGA CAG GAG GAC GAG GGC AAC GGG GCC CAG TAC AGG GGT ATC  
 2136  
 Met Glu Gly Gln Glu Asp Glu Gly Asn Gly Ala Gln Tyr Arg Gly Ile  
 580 585 590  
 40 CTG GAA GCC TCC TTG GAG CTC TTC AAA TTC ACC ATC GGC ATG GGC GAG  
 2184  
 Leu Glu Ala Ser Leu Glu Leu Phe Lys Phe Thr Ile Gly Met Gly Glu  
 595 600 605  
 45 CTG GCC TTC CAG GAG CAG CTG CAC TTC CGC GGC ATG GTG CTG CTG CTG  
 2232  
 Leu Ala Phe Gln Glu Gln Leu His Phe Arg Gly Met Val Leu Leu Leu  
 610 615 620  
 50 CTG CTG GCC TAC GTG CTG CTC ACC TAC ATC CTG CTG CTC AAC ATG CTC  
 2280  
 Leu Leu Ala Tyr Val Leu Leu Thr Tyr Ile Leu Leu Leu Asn Met Leu  
 625 630 635 640  
 55 ATC GCC CTC ATG AGC GAG ACC GTC AAC AGT GTC GCC ACT GAC AGC TGG  
 2328  
 Ile Ala Leu Met Ser Glu Thr Val Asn Ser Val Ala Thr Asp Ser Trp  
 645 650 655  
 60 AGC ATC TGG AAG CTG CAG AAA GCC ATC TCT GTC CTG GAG ATG GAG AAT  
 2376

Ser Ile Trp Lys Leu Gln Lys Ala Ile Ser Val Leu Glu Met Glu Asn  
660 665 670

GGC TAT TGG TGG TGC AGG AAG AAG CAG CGG GCA GGT GTG ATG CTG ACC  
5 2424  
Gly Tyr Trp Trp Cys Arg Lys Lys Gln Arg Ala Gly Val Met Leu Thr  
675 680 685

GTT GGC ACT AAG CCA GAT GGC AGC CCC GAT GAG CGC TGG TGC TTC AGG  
10 2472  
Val Gly Thr Lys Pro Asp Gly Ser Pro Asp Glu Arg Trp Cys Phe Arg  
690 695 700

GTG GAG GAG GTG AAC TGG GCT TCA TGG GAG CAG ACG CTG CCT ACG CTG  
15 2520  
Val Glu Glu Val Asn Trp Ala Ser Trp Glu Gln Thr Leu Pro Thr Leu  
705 710 715 720

TGT GAG GAC CCG TCA GGG GCA GGT GTC CCT CGA ACT CTC GAG AAC CCT  
20 2568  
Cys Glu Asp Pro Ser Gly Ala Gly Val Pro Arg Thr Leu Glu Asn Pro  
725 730 735

GTC CTG GCT TCC CCT CCC AAG GAG GAT GAG GAT GGT GCC TCT GAG GAA  
25 2616  
Val Leu Ala Ser Pro Pro Lys Glu Asp Glu Asp Gly Ala Ser Glu Glu  
740 745 750

AAC TAT GTG CCC GTC CAG CTC CTC CAG TCC AAC TGATGGCCCA GATGCAGCAG  
30 2669  
Asn Tyr Val Pro Val Gln Leu Leu Gln Ser Asn  
755 760

GAGGCCAGAG GACAGAGCAG AGGATCTTTC CAACCACATC TGCTGGCTCT GGGGTCCCAG  
35 2729

TGAATTCTGG TGGCAAATAT ATATTTTCAC TAACTAAAAA AAAAAAAAAA AAAA  
2783

40 (2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 763 amino acids  
45 (B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

50 Met Thr Ser Pro Ser Ser Ser Pro Val Phe Arg Leu Glu Thr Leu Asp  
1 5 10 15

Gly Gly Gln Glu Asp Gly Ser Glu Ala Asp Arg Gly Lys Leu Asp Phe  
55 20 25 30

Gly Ser Gly Leu Pro Pro Met Glu Ser Gln Phe Gln Gly Glu Asp Arg  
35 40 45

60



Lys Phe Ala Pro Gln Ile Arg Val Asn Leu Asn Tyr Arg Lys Gly Thr  
 50 55 60  
 Gly Ala Ser Gln Pro Asp Pro Asn Arg Phe Asp Arg Asp Arg Leu Phe  
 5 65 70 75 80  
 Asn Ala Val Ser Arg Gly Val Pro Glu Asp Leu Ala Gly Leu Pro Glu  
 85 90 95  
 10 Tyr Leu Ser Lys Thr Ser Lys Tyr Leu Thr Asp Ser Glu Tyr Thr Glu  
 100 105 110  
 Gly Ser Thr Gly Lys Thr Cys Leu Met Lys Ala Val Leu Asn Leu Lys  
 115 120 125  
 15 Asp Gly Val Asn Ala Cys Ile Leu Pro Leu Leu Gln Ile Asp Arg Asp  
 130 135 140  
 Ser Gly Asn Pro Gln Pro Leu Val Asn Ala Gln Cys Thr Asp Asp Tyr  
 20 145 150 155 160  
 Tyr Arg Gly His Ser Ala Leu His Ile Ala Ile Glu Lys Arg Ser Leu  
 165 170 175  
 25 Gln Cys Val Lys Leu Leu Val Glu Asn Gly Ala Asn Val His Ala Arg  
 180 185 190  
 Ala Cys Gly Arg Phe Phe Gln Lys Gly Gln Gly Thr Cys Phe Tyr Phe  
 195 200 205  
 30 Gly Glu Leu Pro Leu Ser Leu Ala Ala Cys Thr Lys Gln Trp Asp Val  
 210 215 220  
 Val Ser Tyr Leu Leu Glu Asn Pro His Gln Pro Ala Ser Leu Gln Ala  
 35 225 230 235 240  
 Thr Asp Ser Gln Gly Asn Thr Val Leu His Ala Leu Val Met Ile Ser  
 245 250 255  
 40 Asp Asn Ser Ala Glu Asn Ile Ala Leu Val Thr Ser Met Tyr Asp Gly  
 260 265 270  
 Leu Leu Gln Ala Gly Ala Arg Leu Cys Pro Thr Val Gln Leu Glu Asp  
 275 280 285  
 45 Ile Arg Asn Leu Gln Asp Leu Thr Pro Leu Lys Leu Ala Ala Lys Glu  
 290 295 300  
 Gly Lys Ile Glu Ile Phe Arg His Ile Leu Gln Arg Glu Phe Ser Gly  
 50 305 310 315 320  
 Leu Ser His Leu Ser Arg Lys Phe Thr Glu Trp Cys Tyr Gly Pro Val  
 325 330 335  
 55 Arg Val Ser Leu Tyr Asp Leu Ala Ser Val Asp Ser Cys Glu Glu Asn  
 340 345 350  
 Ser Val Leu Glu Ile Ile Ala Phe His Cys Lys Ser Pro His Arg His  
 355 360 365  
 60

Arg Met Val Val Leu Glu Pro Leu Asn Lys Leu Leu Gln Ala Lys Trp  
 370 375 380  
 5 Asp Leu Leu Ile Pro Lys Phe Phe Leu Asn Phe Leu Cys Asn Leu Ile  
 385 390 395 400  
 Tyr Met Phe Ile Phe Thr Ala Val Ala Tyr His Gln Pro Thr Leu Lys  
 405 410 415  
 10 Lys Ala Ala Pro His Leu Lys Ala Glu Val Gly Asn Ser Met Leu Leu  
 420 425 430  
 Thr Gly His Ile Leu Ile Leu Leu Gly Gly Ile Tyr Leu Leu Val Gly  
 435 440 445  
 15 Gln Leu Trp Tyr Phe Trp Arg Arg His Val Phe Ile Trp Ile Ser Phe  
 450 455 460  
 20 Ile Asp Ser Tyr Phe Glu Ile Leu Phe Leu Phe Gln Ala Leu Leu Thr  
 465 470 475 480  
 Val Val Ser Gln Val Leu Cys Phe Leu Ala Ile Glu Trp Tyr Leu Pro  
 485 490 495  
 25 Leu Leu Val Ser Ala Leu Val Leu Gly Trp Leu Asn Leu Leu Tyr Tyr  
 500 505 510  
 Thr Arg Gly Phe Gln His Thr Gly Ile Tyr Ser Val Met Ile Gln Lys  
 515 520 525  
 30 Val Ile Leu Arg Asp Leu Leu Arg Phe Leu Leu Ile Tyr Leu Val Phe  
 530 535 540  
 35 Leu Phe Gly Phe Ala Val Ala Leu Val Ser Leu Ser Gln Glu Ala Trp  
 545 550 555 560  
 Arg Pro Glu Ala Pro Thr Gly Pro Asn Ala Thr Glu Ser Val Gln Pro  
 565 570 575  
 40 Met Glu Gly Gln Glu Asp Glu Gly Asn Gly Ala Gln Tyr Arg Gly Ile  
 580 585 590  
 Leu Glu Ala Ser Leu Glu Leu Phe Lys Phe Thr Ile Gly Met Gly Glu  
 595 600 605  
 45 Leu Ala Phe Gln Glu Gln Leu His Phe Arg Gly Met Val Leu Leu Leu  
 610 615 620  
 50 Leu Leu Ala Tyr Val Leu Leu Thr Tyr Ile Leu Leu Leu Asn Met Leu  
 625 630 635 640  
 Ile Ala Leu Met Ser Glu Thr Val Asn Ser Val Ala Thr Asp Ser Trp  
 645 650 655  
 55 Ser Ile Trp Lys Leu Gln Lys Ala Ile Ser Val Leu Glu Met Glu Asn  
 660 665 670  
 Gly Tyr Trp Trp Cys Arg Lys Lys Gln Arg Ala Gly Val Met Leu Thr  
 675 680 685  
 60

Val Gly Thr Lys Pro Asp Gly Ser Pro Asp Glu Arg Trp Cys Phe Arg  
690 695 700

Val Glu Glu Val Asn Trp Ala Ser Trp Glu Gln Thr Leu Pro Thr Leu  
5 705 710 715 720

Cys Glu Asp Pro Ser Gly Ala Gly Val Pro Arg Thr Leu Glu Asn Pro  
725 730 735

10 Val Leu Ala Ser Pro Pro Lys Glu Asp Glu Asp Gly Ala Ser Glu Glu  
740 745 750

Asn Tyr Val Pro Val Gln Leu Leu Gln Ser Asn  
755 760

15

## CLAIMS :

1. An isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide  
5 sequence encoding the HVRCC polypeptide of SEQ ID NO:2 over its entire length; or a nucleotide sequence complementary to said nucleotide sequence.
2. The polynucleotide of claim 1 which is DNA or RNA.
- 10 3. A polynucleotide according to one of claims 1 and 2 wherein said nucleotide sequence is at least 80% identical to that contained in SEQ ID NO:1.
- 15 4. A polynucleotide according to one of claims 1 and 3 wherein said nucleotide sequence comprises the HVRCC polypeptide encoding sequence contained in SEQ ID NO:1.
- 20 5. A polynucleotide according to one of claims 1 and 4 which is polynucleotide of SEQ ID NO: 1.
6. An isolated HVRCC polynucleotide comprising a nucleotide sequence selected from the group consisting of :  
(a) a nucleotide sequence having at least 80% identity to a  
25 nucleotide sequence encoding the HVRCC polypeptide expressed by the cDNA insert deposited at the ATCC with Deposit Number 209625 ; and  
(b) a nucleotide sequence complementary to the nucleotide  
sequence of (a).
- 30 7. A DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing a HVRCC polypeptide comprising an amino acid sequence, which has at least 80% identity with the polypeptide of SEQ ID  
35 NO:2 when said expression system is present in a compatible host cell.

8. A host cell comprising the expression system of claim 7.

9. A process for producing a HVRCC polypeptide comprising culturing a host of claim 8 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.

10. A process for producing a cell which produces a HVRCC polypeptide thereof comprising transforming or transfecting a host cell with the expression system of claim 7 such that the host cell, under appropriate culture conditions, produces a HVRCC polypeptide.

11. A HVRCC polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO:2 over its entire length.

12. The polypeptide of claim 11 which comprises the amino acid sequence of SEQ ID NO:2.

13. An antibody immunospecific for the HVRCC polypeptide of claim 11.

14. Use of (a) a therapeutically effective amount of an agonist of HVRCC polypeptide of claim 11 and/or (b) a polynucleotide according to one of claims 1 to 6 in a form so as to effect production of said HVRCC polypeptide activity in vivo, for the manufacture of a medicament for the treatment of a subject in need of enhanced activity or expression of HVRCC polypeptide.

15. Use of (a) a therapeutically effective amount of an antagonist of HVRCC polypeptide of claim 11 and/or (b) a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said HVRCC polypeptide and/or (c) a therapeutically effective amount of a polypeptide that competes with said HVRCC polypeptide, for the manufacture of

a medicament for the treatment of a subject having need to inhibit activity or expression of HVRCC polypeptide.

16. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of HVRCC polypeptide of claim 11 in a subject comprising:
- (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said HVRCC polypeptide in the genome of said subject; and/or
  - (b) analyzing for the presence or amount of the HVRCC polypeptide expression in a sample derived from said subject.

17. A method for identifying agonists to HVRCC polypeptide of claim 11 comprising:

- (a) contacting cells produced by claim 10 with a candidate compound; and
- (b) determining whether the candidate compound effects a signal generated by activation of the HVRCC polypeptide.

20

18. An agonist identified by the method of claim 17.

19. The method for identifying antagonists to HVRCC polypeptide of claim 11 comprising:

- (a) contacting said cell produced by claim 10 with an agonist; and
- (b) determining whether the signal generated by said agonist is diminished in the presence of a candidate compound.

30

20. An antagonist identified by the method of claim 19.

1/4




FIGURE 1

SUBSTITUTE SHEET (RULE 26)

2/4




FIGURE 2

SUBSTITUTE SHEET (RULE 26)



3/4




FIGURE 3

SUBSTITUTE SHEET (RULE 26)

4/4




FIGURE 4

SUBSTITUTE SHEET (RULE 26)



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/12, C07K 14/705, 16/28, A61K 38/17, C12Q 1/68, G01N 33/50, A61K 31/70</b>		A3	(11) International Publication Number: <b>WO 99/46377</b>
			(43) International Publication Date: 16 September 1999 (16.09.99)
(21) International Application Number: <b>PCT/EP99/01550</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 10 March 1999 (10.03.99)		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 98400565.2 11 March 1998 (11.03.98) EP			
(71) Applicant (for all designated States except US): SANOFI-SYNTHELABO [FR/FR]; 174, avenue de France, F-75013 Paris (FR).			
(72) Inventors; and (75) Inventors/Applicants (for US only): PARTISETI, Michel [FR/FR]; 72, rue Velpeau, F-92160 Antony (FR). RENARD, Stéphane [FR/FR]; 290, avenue Napoléon Bonaparte, F-92500 Rueil Malmaison (FR).			
(74) Agent: BUREAU D.A. CASALONGA-JOSSE; Morassistrasse 8, D-80469 Munich (DE).		(88) Date of publication of the international search report: 04 November 1999 (04.11.1999)	
(54) Title: A HUMAN VANILLOID RECEPTOR-LIKE CATION CHANNEL			
(57) Abstract			
<p>hVRCC polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hVRCC polypeptides and polynucleotides in the design of protocols for the treatment of acute and chronic inflammation, acute and chronic pain, brain diseases, abnormal proliferation and cancer, ulcer, autoimmune diseases, control of viscera innervated by the dorsal root ganglia neurons (for instance control of bladder function or dysfunction), to mimic or antagonize effect of endogenous neurotransmitters and hormones, to inhibit graft rejection by promoting immunosuppression, among others and diagnostic assays for such conditions.</p>			
<div style="display: flex; align-items: center;"> <div style="margin-right: 20px;">3.2 Kb →</div> </div>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

Patent Application No  
PCT/EP99/01550

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/705 C07K16/28 A61K38/17 C12Q1/68  
G01N33/50 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CATERINA, MICHAEL J. ET AL: "The capsaicin receptor: a heat-activated ion channel in the pain pathway" NATURE (LONDON), 1997, 389, 816-824, XP002075020 cited in the application	18,20
Y	page 822 - page 823; figures 2,5	1-6,11, 12
X	BIRO T ET AL: "Recent advances in understanding of vanilloid receptors: a therapeutic target for treatment of pain and inflammation in skin." J INVESTIG DERMATOL SYMP PROC, AUG 1997, 2 (1) P56-60, XP002075021 UNITED STATES	18,20
Y	abstract; figure 1; tables I,II	1-6,11, 12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 September 1999

Date of mailing of the international search report

14/09/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Espen, J

# INTERNATIONAL SEARCH REPORT

Application No  
PCT/EP 99/01550

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SZALLASI A ET AL: "A novel agonist, phorbol 12-phenylacetate 13-acetate 20-homovanillate, abolishes positive cooperativity of binding by the vanilloid receptor."  EUR J PHARMACOL, MAR 28 1996, 299 (1-3)  P221-8, XP002059195  NETHERLANDS  figure 6</p> <p style="text-align: center;">---</p>	18,20
P,X	<p>WO 99 09140 A (BRAKE A ;JULIUS D J (US); CATERINA M (US) UNIV CALIFORNIA (US))  25 February 1999 (1999-02-25)  SEQ IDs 5-7,20-23  page 9 - page 10  examples 14,15</p> <p style="text-align: center;">---</p>	1-3,6,11
T	<p>CATERINA ET AL: "A capsaicin-receptor homologue with a high threshold for noxious heat"  NATURE,  vol. 398, no. 398,  1 April 1999 (1999-04-01), pages 436-441  441, XP002105951  ISSN: 0028-0836</p> <p style="text-align: center;">-----</p>	

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/ 01550

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 16  
is directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☒ Claims Nos.: 18,20 in part. 14,15  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:  
See FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 18,20, in part:14,15

Claims 14,15,18,20 relate to agonists or antagonists without giving a true technical characterization. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



### Information on patent family members

PCT/EP-99/01550

Form PCT/ISA/210 (patent family annex) (July 1992)

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**